Human papillomavirus vaccine trials and tribulations

As of December 2014, there were 3 approved vaccines for human papillomavirus (HPV): bivalent Cervarix (GlaxoSmithKline, New York, NY), quadrivalent Gardasil (Merck and Co, Kenilworth, NJ), and 9-valent Gardasil-9 (Merck and Co). The average cost per dose is $120, with a recommended 3-dose course. Th...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American Academy of Dermatology 2015-11, Vol.73 (5), p.759-767
Main Authors: Handler, Nancy S., BA, Handler, Marc Z., MD, Majewski, Slawomir, MD, Schwartz, Robert A., MD, MPH, DSc (Hon), FRCP (Edin)
Format: Article
Language:English
Subjects:
anal cancer
Cervarix
cervical cancer
condylomas
Dermatology
Gardasil
human papillomavirus
vaccine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:As of December 2014, there were 3 approved vaccines for human papillomavirus (HPV): bivalent Cervarix (GlaxoSmithKline, New York, NY), quadrivalent Gardasil (Merck and Co, Kenilworth, NJ), and 9-valent Gardasil-9 (Merck and Co). The average cost per dose is $120, with a recommended 3-dose course. The quadrivalent vaccine is the most widely administered worldwide. As with the bivalent and 9-valent vaccines, the vaccine is considered safe, although concerns have been raised. In addition to immunization against the targeted HPV types, there is evidence that there is cross protection against other types of HPV. This continuing medical education review evaluates the differences in vaccines that are currently on the market; part II focuses on the cost-effectiveness of vaccination, the HPV vaccination programs currently instituted around the globe, efficacy, and safety.
ISSN:0190-9622
1097-6787
DOI:10.1016/j.jaad.2015.05.041